---
figid: PMC9626029__10-1055-a-1896-7092-i220111-4
figtitle: 'Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes
  and Evaluation'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC9626029
filename: 10-1055-a-1896-7092-i220111-4.jpg
figlink: /pmc/articles/PMC9626029/figure/FI220111-4/
number: F4
caption: 'Recommended pathway to evaluate bleeding phenotypes in Waldenström macroglobulinemia,
  with treatment options. Blue: asymptomatic WM; red: symptomatic WM; green: therapy
  recommendations  (Castillo et al 2019). ADAM10, a disintegrin and metalloproteinase
  10; Ag, antigen; aPTT, activated partial thromboplastin time; BM, bone marrow; CBA,
  collagen binding assay; DOAC, direct oral anticoagulant; FBC, full blood count;
  FVIII, factor VIII; IgM, immunoglobulin M; LTA, light transmission aggregometry;
  PFA, platelet function analyzer; PT, prothrombin time; RBC, red blood cell; R:Co:
  ristocetin cofactor assay; ROTEM, rotational thromboelastometry; SE, side effect;
  sGPVI, soluble glycoprotein VI; TEG, thromboelastography; TKI, tyrosine kinase inhibitor;
  VWD, von Willebrand disease; VWF, von Willebrand factor.'
papertitle: 'Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes
  and Evaluation.'
reftext: Simone A. Brysland, et al. Thromb Haemost. 2022 Nov;122(11):1843-1857.
year: '2022'
doi: 10.1055/a-1896-7092
journal_title: Thrombosis and Haemostasis
journal_nlm_ta: Thromb Haemost
publisher_name: Georg Thieme Verlag KG
keywords: platelet | Waldenström macroglobulinemia | receptor | bleeding
automl_pathway: 0.5353008
figid_alias: PMC9626029__F4
figtype: Figure
redirect_from: /figures/PMC9626029__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9626029__10-1055-a-1896-7092-i220111-4.html
  '@type': Dataset
  description: 'Recommended pathway to evaluate bleeding phenotypes in Waldenström
    macroglobulinemia, with treatment options. Blue: asymptomatic WM; red: symptomatic
    WM; green: therapy recommendations  (Castillo et al 2019). ADAM10, a disintegrin
    and metalloproteinase 10; Ag, antigen; aPTT, activated partial thromboplastin
    time; BM, bone marrow; CBA, collagen binding assay; DOAC, direct oral anticoagulant;
    FBC, full blood count; FVIII, factor VIII; IgM, immunoglobulin M; LTA, light transmission
    aggregometry; PFA, platelet function analyzer; PT, prothrombin time; RBC, red
    blood cell; R:Co: ristocetin cofactor assay; ROTEM, rotational thromboelastometry;
    SE, side effect; sGPVI, soluble glycoprotein VI; TEG, thromboelastography; TKI,
    tyrosine kinase inhibitor; VWD, von Willebrand disease; VWF, von Willebrand factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Sps1
  - mid
  - pt
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Bm
  - teg
  - ag
  - kuz
  - Kul
  - if
  - CD40LG
  - RN7SL263P
  - LTA
  - YES1
  - VWF
  - F8
  - ADAM10
  - PFA
  - bleeding
  - headaches
  - confusion
  - visual loss
  - deafness
  - Abnormal VWF
  - VWD
---
